^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

ET 019003

i
Other names: ET-019003, ET 019003, ET019003, ET019003-T cells, anti-CD19 CAR-T cells
Associations
Trials
Company:
Eureka Therap
Drug class:
CD19-targeted CAR-T immunotherapy, γδ TCR modulator
Related drugs:
Associations
Trials
almost2years
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma. (PubMed, J Hematol Oncol)
CD19-specific γ/δ TCR-T cells, ET019003, had a good safety profile and could induce rapid responses and durable CR in patients with relapsed or refractory DLBCL, even primary CNS lymphoma, presenting a novel and potent therapeutic option for these patients.
Journal
|
CD19 (CD19 Molecule)
|
ET 019003
over2years
A novel antibody-TCR (AbTCR) T-cell therapy is safe and effective against CD19-positive relapsed/refractory B-cell lymphoma. (PubMed, J Cancer Res Clin Oncol)
This study provides initial clinical validation of the AbTCR platform as a novel cancer treatment with the potential to provide durable clinical benefit with low toxicity.
Journal
|
CD19 (CD19 Molecule)
|
CD19 positive
|
ET 019003
3years
ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma (clinicaltrials.gov)
P1, N=9, Active, not recruiting, Wuhan Union Hospital, China | Recruiting --> Active, not recruiting | N=18 --> 9
Clinical • Enrollment closed • Enrollment change
|
CD19 (CD19 Molecule)
|
ET 019003
3years
Novel CD19-Specific γ/δ TCR-T Cells in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (ASH 2021)
We previously developed a human anti-CD19 antibody (ET190L1), and found that ET190L1-TCR-T cells maintained comparable anti-tumor potency with less cytokine release to CD28-costimulated ET190L1-CAR and CD137-based CTL019 T cells (Cell Discov...Cyclophosphamide 250 mg/m 2 on day -5 and fludarabine 25 mg/m 2 on day -5 to -3 were used as the conditioning regimen... These data suggest ET019003-T cells had a good safety profile and could induce durable remission in patients with RR DLBCL, even with primary CNS lymphoma. γ/δ TCR-T cells may present a potential therapeutic option for these patients.
PD(L)-1 Biomarker • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD19 (CD19 Molecule) • BCL6 (B-cell CLL/lymphoma 6) • IL6 (Interleukin 6) • TNFRSF9 (TNF Receptor Superfamily Member 9)
|
IL6 elevation • MYC expression
|
cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV • ET 019003
almost4years
ET019003-T Cells in Relapsed/Refractory CD19+ B-Cell Leukemia and Lymphoma (clinicaltrials.gov)
P1, N=18, Recruiting, Wuhan Union Hospital, China | N=50 --> 18
Clinical • Enrollment change
|
CD19 (CD19 Molecule)
|
ET 019003